PHCCC

Pricing Availability   Qty
说明: Potent group I mGlu antagonist
化学名: N-Phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide
纯度: ≥98% (HPLC)
说明书
引用文献 (8)
评论
文献 (5)

生物活性 for PHCCC

PHCCC is a group I metabotropic glutamate receptor antagonist (IC50 ~ 3 μM); 67 times more potent than (S)-4-carboxyphenylglycine (Cat. No. 0323). Also a positive allosteric modulator for mGlu4a; potentiates L-AP4-mediated inhibition of striatopallidal synaptic transmission in vitro. Displays antiParkinsonian effects in rats in vivo.

许可信息

Sold for research purposes under license from Suntory Ltd.

化合物库 for PHCCC

PHCCC is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。

技术数据 for PHCCC

分子量 294.31
公式 C17H14N2O3
储存 Store at RT
纯度 ≥98% (HPLC)
CAS Number 179068-02-1
PubChem ID 5866327
InChI Key FPXPIEZPAXSELW-CYVLTUHYSA-N
Smiles O=C(NC4=CC=CC=C4)C3(C2C3)OC1=CC=CC=C1/C2=N/O

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for PHCCC

溶剂 最高浓度 mg/mL 最高浓度 mM
溶解性
DMSO 29.43 100

制备储备液 for PHCCC

以下数据基于产品分子量 294.31。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

选择批次从而根据批次分子量重新计算:
浓度/溶剂体积/质量 1 mg 5 mg 10 mg
1 mM 3.4 mL 16.99 mL 33.98 mL
5 mM 0.68 mL 3.4 mL 6.8 mL
10 mM 0.34 mL 1.7 mL 3.4 mL
50 mM 0.07 mL 0.34 mL 0.68 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

产品说明书 for PHCCC

分析证书/产品说明书
选择另一批次:

参考文献 for PHCCC

参考文献是支持产品生物活性的出版物。

Mao and Wang (2001) Selective activation of group I metabotropic glutamate receptors upregulates preprodynorphin, substance P and preproenkephalin mRNA expression in rat dorsal striatum. Synapse 39 82 PMID: 11071713

Marino et al (2003) Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc.Natl.Acad.Sci.USA 100 13668 PMID: 14593202

Annoura et al (1996) A novel class of antagonists for metabotropic glutamate receptors, 7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxylates. Bioorg.Med.Chem.Lett. 6 763

Flor et al (2002) Positive allosteric modulators of metabotropic glutamate receptor subtype 4: pharmacological and molecular characterization. Neuropharmacology 43 286 Abstr.No. 47


If you know of a relevant reference for PHCCC, please let us know.

关键词: PHCCC, PHCCC supplier, Potent, group, I, mGlur, antagonists, Group, Receptors, mGlu1, mGlu5, Glutamate, Metabotropic, mGlu4, (Metabotropic), 1027, Tocris Bioscience

8 篇 PHCCC 的引用文献

引用文献是使用了 Tocris 产品的出版物。 PHCCC 的部分引用包括:

Spampinato et al (2015) Glial metabotropic glutamate receptor-4 increases maturation and survival of oligodendrocytes. Biol Psychiatry 8 462 PMID: 25642169

Volpi et al (2016) Allosteric modulation of metabotropic glutamate receptor 4 activates IDO1-dependent, immunoregulatory signaling in dendritic cells. Neuropharmacology 102 59 PMID: 26522434

Broadstock et al (2012) Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata. Br J Pharmacol 165 1034 PMID: 21627638

Niswender et al (2008) Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol Pharmacol 74 1345 PMID: 18664603


您是否知道使用了 Tocris PHCCC 的优秀论文? 请告知我们.

PHCCC 的评论

目前没有该产品的评论。 Be the first to review PHCCC and earn rewards!

Have you used PHCCC?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Metabotropic Glutamate Receptors Scientific Review

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.